Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

BOSTON -- Pulsed field ablation (PFA) trials continued to accrue positive data, as reported at the Heart Rhythm Society (HRS) annual meeting. Secondary analysis of the pivotal ADVENT trial showed that ...

Radiofrequency-based ablation for atrial fibrillation appears more effective than previously shown in clinical trials. Using real-world data, a new study found that the procedure eliminated atrial ...

The efficacy of catheter ablation for heart failure (HF) patients with atrial fibrillation (Afib or AF) hinged on the phenotype of disease, researchers reported based on a meta-analysis. Compared with ...

Successful catheter ablation resulted in a low risk of stroke associated with atrial fibrillation (AFib), a type of irregular heart rhythm, according to an international study. Researchers said these ...